Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$808.61 USD

808.61
907,273

-10.32 (-1.26%)

Updated Nov 4, 2024 10:34 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

Amgen (AMGN) Q1 Earnings Top, Sales Hurt by Pricing Pressure

Amgen (AMGN) earnings beat estimates in the first quarter while sales come in line with the same. The company raises the lower end of its previously issued sales and earnings guidance for 2019.

Benjamin Rains headshot

3 Tech Stocks for Growth Investors to Buy Right Now

Let's check out three tech stocks that came through our screen today that growth investors might want to consider at the moment...

Lilly (LLY) Down Despite Q1 Earnings Beat on Sales View Cut

Eli Lilly's (LLY) earnings beat estimates in Q1. Stock falls in pre-market trading as the company lowers its full-year revenue forecast.

Incyte (INCY) Q1 Earnings & Revenues Beat Estimates, Up Y/Y

While Incyte's (INCY) earnings and revenues beat estimates in Q1, Jakafi sales fall short of the same.

Looking for a Growth Stock? 3 Reasons Why Lilly (LLY) is a Solid Choice

Lilly (LLY) is well positioned to outperform the market, as it exhibits above-average growth in financials.

5 Drug/Biotech Stocks Poised to Beat Q1 Earnings Estimates

So far, the going seems good for the drug/biotech sector this earnings season. Let us take a glance at a few other companies, which hold promise to beat on Q1 earnings.

AstraZeneca's (AZN) Q1 Earnings Beat, New Drugs Drive Sales

AstraZeneca (AZN) beats earnings and sales estimates in the first quarter. New drugs, especially cancer drugs, drive revenues.

Sanofi (SNY) Q1 Earnings Top, Genzyme & Vaccines Drive Sales

Sanofi's first-quarter 2019 results were mixed as it beat estimates for earnings but missed the same for sales.

Bayer (BAYRY) Q1 Earnings Beat Estimates, Revenues Up Y/Y

Bayer (BAYRY) exceeds earnings estimates in the first quarter of 2019 and sales rise year over year.

Kinjel Shah headshot

Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead to an earnings beat for the company in Q1.

Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline

Share price of Novo Nordisk (NVO) has increased year to date on strong presence in the Diabetes Care market and a solid pipeline.

Radius Health (RDUS) Rallies 33.4% YTD on Robust Tymlos Sales

Radius Health's (RDUS) lead drug, Tymlos, gains traction in 2018. Let us see how the drug will fare in 2019 amid increasing competition.

J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer

FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months

Sweta Jaiswal, FRM headshot

Biotechnology Market on a Tear: 5 ETFs in Spotlight

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.

The Zacks Analyst Blog Highlights: Eli Lilly, Altria, Becton, Dickinson, T-Mobile and General Motors

The Zacks Analyst Blog Highlights: Eli Lilly, Altria, Becton, Dickinson, T-Mobile and General Motors

Why Eli Lilly (LLY) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

Looking for a Growth Stock? 3 Reasons Why Lilly (LLY) is a Solid Choice

Lilly (LLY) could produce exceptional returns because of its solid growth attributes.

Mark Vickery headshot

Top Stock Reports for Eli Lilly, Altria & Becton Dickinson

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly (LLY), Altria (MO) and Becton, Dickinson (BDX).

United Therapeutics Discontinues PAH Drug After Study Fails

United Therapeutics (UTHR) discontinues the development of esuberaprost, as the phase III study fails to meet primary endpoint.

Kinjel Shah headshot

Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men

Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.

Kinjel Shah headshot

Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men

Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.

Novartis & Amgen in Legal Dispute Over Migraine Drug Aimovig

Novartis (NVS) sues Amgen as the latter issues termination notice for migraine drug.

Swarup Gupta headshot

Dow 30 Stock Roundup: WBA Q2 Earnings Disappoint, PFE Lung Cancer Drug Gets EU Approval

The index notched up another week of gains riding on optimism over the increasing likelihood of a U.S.-China trade deal.

Sanghamitra Saha headshot

Health Day Checkup of Medical ETFs: 5 Top Picks

M&A activity, approval of novel drugs and earnings growth in Q1 put healthcare ETFs in a decent spot.